Effects of Clinical Mutations in the Second Coordination Sphere and Remote Regions on the Catalytic Mechanism of Non‐Heme Fe(II)/2‐Oxoglutarate‐Dependent Aspartyl Hydroxylase AspH
ChemPhysChem · 2024
DOI: 10.1002/cphc.202400303 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemPhysChem, 2024. Verfasst von Anandhu Krishnan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Michigan Technological University, Houghton, MI-49931, USA. Hauptthemen laut MEDLINE: Mixed Function Oxygenases, Ketoglutaric Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS, Cancer Research UK.
Abstract (Originalsprache)
Aspartyl/asparaginyl hydroxylase (AspH) catalyzes the post‐translational hydroxylations of vital human proteins, playing an essential role in maintaining their biological functions. Single‐point mutations in the Second Coordination Sphere (SCS) and long‐range (LR) residues of AspH have been linked to pathological conditions such as the ophthalmologic condition Traboulsi syndrome and chronic kidney disease (CKD). Although the clinical impacts of these mutations are established, there is a critical knowledge gap regarding their specific atomistic effects on the catalytic mechanism of AspH. In this study, we report integrated computational investigations on the potential mechanistic implications of four mutant forms of human AspH with clinical importance: R735W, R735Q, R688Q, and G434V. All the mutant forms exhibited altered binding interactions with the co‐substrate 2‐oxoglutarate (2OG) and the main substrate in the ferric‐superoxo and ferryl complexes, which are critical for catalysis, compared to the wild‐type (WT). Importantly, the mutations strongly influence the energetics of the frontier molecular orbitals (FMOs) and, thereby, the activation energies for the hydrogen atom transfer (HAT) step compared to the WT AspH. Insights from our study can contribute to enzyme engineering and the development of selective modulators for WT and mutants of AspH, ultimately aiding in treating cancers, Traboulsi syndrome and, CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Michigan Technological University, Houghton, MI-49931, USA.
- Department of Chemical Engineering, Michigan Techno, Department of Chemistry, Michigan Technological University, Houghton, MI-49931, USA.
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, OX1 3TA, United Kingdom.
ORCID-Profile: Anandhu Krishnan, Sodiq O Waheed, Christopher J Schofield, Tatyana G Karabencheva-Christova
Förderung
- NIGMS NIH HHS
- NIH HHS
- Cancer Research UK
- Michigan Technological University Health Research Institute (HRI)
- National Institutes of Health
Zitieren
APA
Krishnan, A., Waheed, S. O., Melayikandy, S., LaRouche, C., Paik, M., Schofield, C. J., & Karabencheva-Christova, T. G. (2024). Effects of Clinical Mutations in the Second Coordination Sphere and Remote Regions on the Catalytic Mechanism of Non‐Heme Fe(II)/2‐Oxoglutarate‐Dependent Aspartyl Hydroxylase AspH. ChemPhysChem. https://doi.org/10.1002/cphc.202400303
Vancouver
Krishnan A, Waheed SO, Melayikandy S, LaRouche C, Paik M, Schofield CJ, et al. Effects of Clinical Mutations in the Second Coordination Sphere and Remote Regions on the Catalytic Mechanism of Non‐Heme Fe(II)/2‐Oxoglutarate‐Dependent Aspartyl Hydroxylase AspH. ChemPhysChem. 2024. doi:10.1002/cphc.202400303
BibTeX
@article{Krishnan2024,
author = {Krishnan, Anandhu and Waheed, Sodiq O and Melayikandy, Sreerag and LaRouche, Ciara and Paik, Meredith and Schofield, Christopher J and Karabencheva-Christova, Tatyana G},
title = {Effects of Clinical Mutations in the Second Coordination Sphere and Remote Regions on the Catalytic Mechanism of Non‐Heme Fe(II)/2‐Oxoglutarate‐Dependent Aspartyl Hydroxylase AspH},
journal = {ChemPhysChem},
year = {2024},
doi = {10.1002/cphc.202400303}
}
EUVIMED